for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.AS

Latest Trade

155.80EUR

Change

-2.70(-1.70%)

Volume

255,238

Today's Range

152.95

 - 

160.00

52 Week Range

130.80

 - 

252.90

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
158.50
Open
160.00
Volume
255,238
3M AVG Volume
9.02
Today's High
160.00
Today's Low
152.95
52 Week High
252.90
52 Week Low
130.80
Shares Out (MIL)
64.82
Market Cap (MIL)
10,453.78
Forward P/E
-195.63
Dividend (Yield %)
--

Next Event

Q2 2020 Galapagos NV Earnings Release

Latest Developments

More

Gilead And Galapagos Announce Positive European CHMP Opinion For Jyseleca

Galapagos: Capital Increase Of EUR 17.9 Million

Gilead, Galapagos Announce Topline Results Of Phase 2b/3 Trial In Ulcerative Colitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Industry

Biotechnology & Drugs

Contact Info

Generaal De Wittelaan 3

2800

Belgium

+32.15.342900

http://www.glpg.com

Executive Leadership

Onno van de Stolpe

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Rajesh B. Parekh

Non-Executive Chairman of the Board

Bart Filius

Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer

Piet Wigerinck

Member of the Executive Committee, Chief Scientific Officer

Michele Manto

Chief Commercial Officer

Key Stats

2.50 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.2K

2018

0.3K

2019

0.9K

2020(E)

0.6K
EPS (EUR)

2017

-2.340

2018

-0.560

2019

2.490

2020(E)

-0.815
Price To Earnings (TTM)
100.22
Price To Sales (TTM)
10.87
Price To Book (MRQ)
3.66
Price To Cash Flow (TTM)
64.62
Total Debt To Equity (MRQ)
0.88
LT Debt To Equity (MRQ)
0.66
Return on Investment (TTM)
4.50
Return on Equity (TTM)
4.00

Latest News

Latest News

BRIEF-E-Therapeutics Announces Collaboration With Galapagos

* E-THERAPEUTICS PLC - COLLABORATION WITH GALAPAGOS TO DISCOVER THERAPEUTIC STRATEGIES FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Source text for Eikon: Further company coverage:

BRIEF-Galapagos: Capital Increase Of EUR 17.9 Million

* ANNOUNCED ON THURSDAY SHARE CAPITAL INCREASE THROUGH SUBSCRIPTION RIGHT EXERCISES

Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc <GILD.O> and partner Galapagos NV <GLPG.AS> said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.

BRIEF-Gilead, Galapagos Announce Topline Results Of Phase 2b/3 Trial In Ulcerative Colitis

* GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Gilead-Galapagos's drug meets main goals of ulcerative colitis study

Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.

BRIEF-Galapagos Q1 Net Loss Widens To 50.6 Million Euros

* ANNOUNCED ON THURSDAY : FIRST THREE-MONTH 2020 FINANCIAL RESULTS

BRIEF-Galapagos Creates New Subscription Right Plans

* GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLANS Source text for Eikon: Further company coverage:

BRIEF-Ryvu Therapeutics Signs R&D Cooperation Deal With Belgium-Based Galapagos

* SIGNS RESEARCH AND DEVELOPMENT COOPERATION DEAL WITH BELGIUM-BASED GALAPAGOS

BRIEF-Galapagos And Ryvu To Partner On Drug Discovery And Development

* TODAY ANNOUNCED A COLLABORATION FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE DRUGS IN INFLAMMATION

BRIEF-Galapagos Reports FY Group Revenues & Other Income Of EUR 896 Million, Compared To EUR 318 Million In 2018

* GALAPAGOS NV - FY GROUP REVENUES & OTHER INCOME OF EUR 896 MILLION, COMPARED TO EUR 318 MILLION IN 2018

BRIEF-Galapagos Announces Share Capital Increase Through Warrant Exercises For EUR 2.7 Mln

* SAID ON MONDAY ISSUED 95,180 NEW ORDINARY SHARES ON NOV 25, FOR TOTAL CAPITAL INCREASE OF EUR 2.7 MLN

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN

CORRECTED-BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV.

Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report

Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Shares in Galapagos jump 15 percent after arthritis drug results

Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up